RxDoctor Payments Data

Shirley Williams, MD

Cardiovascular Disease · Flower Mound, TXNPI 1346298304

Payments from drug & device makers

$5,556in general payments, 2019–2025

Across 323 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$863
  • Merck$787
  • Pfizer$760
  • E.r. Squibb & Sons, L.L.C.$708
  • Sanofi-aventis U.S. LLC$381
  • Boehringer Ingelheim$380
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,553100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,556 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$326,877
Medicare patients
1,526
Services billed
4,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban758$882,539
EntrestoSacubitril/Valsartan190$227,389
XareltoRivaroxaban165$184,085
Repatha SureclickEvolocumab67$74,848
BrilintaTicagrelor41$32,819
MultaqDronedarone Hcl14$22,013
JardianceEmpagliflozin21$20,230
Metoprolol Succinate1,038$14,017
Praluent PenAlirocumab26$12,798
Repatha SyringeEvolocumab18$10,222
Ranolazine ErRanolazine81$9,389
CorlanorIvabradine Hcl11$7,480
Losartan Potassium581$5,904
Diltiazem 24hr Er (Cd)Diltiazem Hcl174$5,376
Flecainide Acetate135$4,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$760$882,539758 claims
NovartisEntresto$863$227,389190 claims
Johnson & JohnsonXarelto$210$184,085165 claims
AstraZenecaBrilinta$99$32,81941 claims
Sanofi-aventis U.S. LLCMultaq$381$22,01314 claims
Boehringer IngelheimJardiance$380$20,23021 claims
AmgenCorlanor$138$7,48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Flower Mound

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →